Free Trial

Diploma (LON:DPLM) Stock Passes Above 200 Day Moving Average - Here's What Happened

Diploma logo with Industrials background

Diploma PLC (LON:DPLM - Get Free Report) shares passed above its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of GBX 4,338.92 ($58.26) and traded as high as GBX 4,942 ($66.35). Diploma shares last traded at GBX 4,942 ($66.35), with a volume of 179,929 shares changing hands.

Diploma Stock Performance

The stock has a 50-day simple moving average of GBX 4,637.05 and a 200-day simple moving average of GBX 4,343.89. The company has a market capitalization of £6.54 billion, a price-to-earnings ratio of 56.37, a price-to-earnings-growth ratio of 2.82 and a beta of 0.75. The company has a current ratio of 2.17, a quick ratio of 0.80 and a debt-to-equity ratio of 62.17.

Diploma (LON:DPLM - Get Free Report) last posted its quarterly earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.08) earnings per share (EPS) for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. On average, analysts anticipate that Diploma PLC will post 163.7995512 earnings per share for the current year.

Insider Activity

In related news, insider Katie Bickerstaffe bought 44 shares of the business's stock in a transaction on Wednesday, May 21st. The shares were bought at an average cost of GBX 4,867 ($65.35) per share, for a total transaction of £2,141.48 ($2,875.24). Over the last quarter, insiders purchased 96 shares of company stock worth $473,173. Corporate insiders own 0.52% of the company's stock.

About Diploma

(Get Free Report)

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

Featured Articles

Should You Invest $1,000 in Diploma Right Now?

Before you consider Diploma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Diploma wasn't on the list.

While Diploma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

5 Stocks to BUY NOW in August 2025
The $2.5B Merger No One Is Talking About
ALERT: Big Tech Earnings – Watch Before Wednesday

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines